Carcinoid Tumor Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

 (Albany, NY) Delveinsight has launched a new report on "Carcinoid Tumor Market Insights, Epidemiology, and Market Forecast-2030”.

 

DelveInsight's "Carcinoid Tumor Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Carcinoid Tumor , historical and forecasted epidemiology as well as the Carcinoid Tumor market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some of the facts:

  • ·         Literature studies suggest that women are more likely to develop carcinoid tumors than men.
  • ·         The incidence of Neuroendocrine tumors was approximately 2/100,000 with a female preponderance under the age of 50 years due to appendiceal location. The main primary sites were the gastrointestinal tract (62–67%) and the lung (22–27%). Presentation with metastatic disease accounts for 12–22%.
  • ·         According to the American Society of Clinical Oncology (ASCO) in 2016, approximately 8,000 adults in the US were diagnosed with a carcinoid tumor in their GI tract.
  • ·         It is estimated that each year approximately 4,000 adults in the United States diagnose with the carcinoid tumor in their lung.

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/carcinoid-tumor-market

 

Scope of the Report:

  • The Carcinoid Tumor report covers the descriptive overview of Carcinoid Tumor , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Carcinoid Tumor epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Carcinoid Tumor are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Carcinoid Tumor market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The Carcinoid Tumor report provides an edge while developing business strategies, by understanding trends shaping and driving the global Carcinoid Tumor market

 

Carcinoid Tumors are a type of slow-growing cancers that can arise in several places throughout the body and are characterized by the production of an excess of hormone-like substances, such as serotonin, bradykinin, histamine, and prostaglandins which leads to the other associated complications. These tumors, are the subset of neuroendocrine tumors and usually begin in the digestive tract (stomach, appendix, small intestine, colon, and rectum) or in the lungs. On the basis of their location of origin, these tumors are categorized into three areas as Foregut: The foregut includes the lungs and the stomach; Midgut: comprised of the small intestine, appendix, and the beginning of the large bowel (colon), and Hindgut: composed of the end of the large bowel, the rectum and the organs of the genitourinary tract (ovaries, testes).

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/carcinoid-tumor-market

 

In the terms of their reported occurrence, CT most commonly develops in the gastrointestinal tract. However, they can also occur in other parts of the body such as the lungs, ovaries, or testicles. Based on the location and size of the tumor, CT usually presents with the subset of the symptoms such as cutaneous flushing, itching, and palpitation, edema, salivation, upper body erythema, chronic diarrhea, malabsorption, and breathing difficulties, etc. Till now, the associated causes of CT remains largely unknown, however common risk factors includes getting affected with disorders, such as multiple endocrine neoplasia, pernicious anemia, or Zollinger- Ellison syndrome, etc.

 

The Key players involved in the Carcinoid Tumor market are:

·         Amgen Inc.

·         Novartis AG

·         Exelixis, Inc.

·         AVEO Pharmaceuticals, Inc.

·         Boehringer Ingelheim GmbH

·         Aegis Therapeutics, LLC

·         Chiasma, Inc.

·         Delcath Systems Inc.

·         CRINETICS PHARMACEUTICALS

·         And Many Others.

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/carcinoid-tumor-market

 

Table of Contents:

1. Key Insights

2. Executive Summary of Carcinoid Tumor

3. Competitive Intelligence Analysis for Carcinoid Tumor

4. Carcinoid Tumor : Market Overview at a Glance

4.1. Carcinoid Tumor Total Market Share (%) Distribution in 2017

4.2. Carcinoid Tumor Total Market Share (%) Distribution in 2030

5. Carcinoid Tumor : Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms 

5.3. Carcinoid Tumor Pathophysiology 

5.4. Carcinoid Tumor Risk Factors 

5.5. Carcinoid Tumor Diagnosis 

6. Patient Journey

7. Carcinoid Tumor Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Carcinoid Tumor Epidemiology Scenario: 7MM

7.3.1. Carcinoid Tumor Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Carcinoid Tumor Epidemiology

7.4.1. Carcinoid Tumor Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Carcinoid Tumor Epidemiology

7.5.1.1. Carcinoid Tumor Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Carcinoid Tumor Epidemiology

7.5.2.1. Carcinoid Tumor Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Carcinoid Tumor Epidemiology

7.5.3.1. Carcinoid Tumor Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Carcinoid Tumor Epidemiology

7.5.4.1. Carcinoid Tumor Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Carcinoid Tumor Epidemiology

7.5.5.1. Carcinoid Tumor Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Carcinoid Tumor Epidemiology

7.5.6.1. Carcinoid Tumor Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Carcinoid Tumor Treatment and Management

8.2. Carcinoid Tumor Treatment Algorithm 

9. Carcinoid Tumor Unmet Needs

10. Key Endpoints of Carcinoid Tumor Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Carcinoid Tumor Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Carcinoid Tumor : Seven Major Market Analysis

13.1. Key Findings

13.2. Carcinoid Tumor Market Size in 7MM

13.3. Carcinoid Tumor Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Carcinoid Tumor Market Size

15.1.1. Carcinoid Tumor Total Market Size in the United States

15.1.2. Carcinoid Tumor Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Carcinoid Tumor Market Size

15.3.1. Carcinoid Tumor Total Market Size in Germany

15.3.2. Carcinoid Tumor Market Size by Therapies in Germany

15.4. France Carcinoid Tumor Market Size

15.4.1. Carcinoid Tumor Total Market Size in France

15.4.2. Carcinoid Tumor Market Size by Therapies in France

15.5. Italy Carcinoid Tumor Market Size

15.5.1. Carcinoid Tumor Total Market Size in Italy

15.5.2. Carcinoid Tumor Market Size by Therapies in Italy

15.6. Spain Carcinoid Tumor Market Size

15.6.1. Carcinoid Tumor Total Market Size in Spain

15.6.2. Carcinoid Tumor Market Size by Therapies in Spain

15.7. United Kingdom Carcinoid Tumor Market Size

15.7.1. Carcinoid Tumor Total Market Size in the United Kingdom

15.7.2. Carcinoid Tumor Market Size by Therapies in the United Kingdom

15.8. Japan Carcinoid Tumor Market Outlook

15.8.1. Japan Market Size

15.8.2. Carcinoid Tumor Total Market Size in Japan

15.8.3. Carcinoid Tumor Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Carcinoid Tumor

17. KOL Views

18. Carcinoid Tumor Market Drivers

19. Carcinoid Tumor Market Barriers

20. Appendix

20.1. Bibliography

20.2. Carcinoid Tumor Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Request for Detailed Toc: https://www.delveinsight.com/sample-request/carcinoid-tumor-market

 

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for

Browse through our vast repository from here.

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: info@delveinsight.com
Phone: +19193216187
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 


Comments

Post a Comment

Popular posts from this blog

How Competitive intelligence is transforming the scenario for Biotech firms?

What is Competitive intelligence service? Competitive intelligence ideally means gathering information on rival business in the market, analyse the information and use the information to strategize to yield positive results. Going by the definition, competitive intelligence assembles actionable information from diverse published and unpublished sources, collected efficiently and ethically. So, analysts performing Competitive intelligence for their clienteles present a detailed picture of the marketplace, forthcoming challenges and the ways to face them, even before the can harm the client’s business. What could it mean? Competitive intelligence can often give a wrong idea, as it may misunderstood as a service which can help gain an advantage over the rivals. However, this is not the case. Competitive intelligence is an ethical and legal practise undertaken involving the study of analytical data, analysing the market and optimizing the relevant and realistic strategies t...
Read more

The Need And The Importance Of The Healthcare Reports for the Pharma Companies

Image
It is very important for the hospitals and the other medical institutions to preserve and keep the healthcare reports of all the patients very safe and secure. All the medical records are being kept by almost all of these institutes. As a matter of fact, the healthcare reports are very important for comprehending the medical history of the patient. If he or she suffers from the same ailment once more the previous reports will be absolutely indispensible while treating him or her. Nowadays, with the advancement of technology the manual records are slowly and gradually getting digitalized. It is easier to store and preserve the digital records than the manual and the physical ones.  Choosing The Best And The Most Professional Services For Healthcare Reports: • Rising Pharma Market for You Now In the market there are a host of companies that preserves the healthcare reports of the various patients. All of it is now being done in the digital format due to the adv...
Read more

Vernal Keratoconjunctivitis Market

(Albany, US) DelveInsight’s “ Vernal Keratoconjunctivitis Market  Insights, Epidemiology, and Market Forecast-2030 ” report provides an in-depth understanding of the disease, historical and forecasted epidemiology, as well as Vernal Keratoconjunctivitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Some of the key facts of the  Vernal Keratoconjunctivitis Market The increasing population and rising prevalence of Vernal Keratoconjunctivitis generates a large patient population in the global market. In 2017, a total of 4,752,356 patients were affected by Vernal Keratoconjunctivitis in the global market. China contributes the largest share among EU-5, and Japan, with 2,248,706 cases in 2017. The total diagnosed prevalent population of Vernal Keratoconjunctivitis was 2,943,057 in the global market.   Request for Sample Report: https://www.delveinsight.com/report-store...
Read more